Navigation Links
Dr. Kent Stobaugh Retiring from Oral & Maxillofacial Surgeons to Pursue Different Opportunities: SA4i Emphasizes Significant Contributions to People’s Lives
Date:1/8/2013

Houston, Texas (PRWEB) January 08, 2013

Dr. Stobaugh is a consummate professional who has contributed toward, even responsible for, immeasurable improvements in the quality of people’s lives. As a result of his dedication and expertise, thousands of people have increased functioning, comfort and confidence in regard to chewing, jaw movement, self-image and so much more.

Oral and Maxillofacial Surgeons (OMS) are surgeons who are extremely specialized. They treat numerous diseases, injuries and defects in the face, jaws, head, and neck as well as the hard and soft tissues of the oral (mouth) and maxillofacial (jaws and face) regions. Adding to the elite status of an OMS is the fact that they complete extensive training in the administration of anesthesia.

As an Oral and Maxillofacial Surgeon (OMS), Dr. Stobaugh is certified by the American Board of Oral and Maxillofacial Surgery (ABOMS). Certification requirements for an OMS by the ABOMS are comprehensive and extensive. They include training in an accredited residency program, post-training experience, as well as the successful completion of a computer-administered examination and an oral examination; both on the entire scope of the specialty.

Dr. Stobaugh received his first and second degrees, a BA in zoology and an MS in pharmacy respectively, from University of Texas at Austin. Dr. Stobaugh then received his D.D.S. degree in 1970 from the University of Texas Dental Branch at Houston followed by a Certificate of Oral and Maxillofacial Surgery in 1973 upon completion of his surgical residency at the Houston V.A. Hospital.

Becoming a general dentist (DDS or DMD) is a great and respectable accomplishment requiring the completion a four-year educational program. Comparatively, relatively few individuals continue to become an Oral and Maxillofacial Surgeon which requires yet an additional four to six years.

Dr. Stobaugh has strongly expressed being honored to have worked with his colleagues at Oral & Maxillofacial Surgeons of Houston as well as his confidence that Dr.’s Paul Metz, Shelley Seidel, and John Orfanos will continue to serve all patients “with great competence and excellent care.”

When not working as a doctor and surgeon, Dr. Stobaugh relishes spending time with his family and is a proud husband, father and grandfather. Activities he enjoys include fishing, golfing, hunting and running.

For more information about OMSH, please call 713-IMPLANT (467-5268). You can also visit the OMSH website at: oralsurgeonhouston.com.

SA4i (Strategic Advisors for the Internet) is an online internet presence management group representing a wide variety businesses. One of SA4i's specialty areas is with medical and healthcare providers, including Oral & Maxillofacial Surgeons of Houston (OMSH).

Read the full story at http://www.prweb.com/releases/SA4i/DrStobaughOMSH/prweb10292000.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Research shows efficacy of treatment model developed at Women & Infants
2. Soy-based S-equol supplement reduces hot flash frequency, muscle & joint pain in US women
3. Vendors in Nevada, Michigan, & Illinois to be Featured on the PartyPOP.com Online Network
4. Beef & Pork Wholesaling in the US Industry Market Research Report Now Available from IBISWorld
5. The Tennessee Car Accident Lawyers at Michael D. Ponce & Associates Alert Public of CDC Survey Revealing Majority of High School Seniors Admitting to Texting Behind Wheel
6. Alex Galindo, Attorney and Partner at Curd, Galindo & Smith, LLP, Court Wins Against the County of Riverside's Motion to Dismiss Medical Malpractice Case
7. Play & Park Structures Included in New Play for All Abilities Playground
8. Gum Disease, HPV May Play Role in Head & Neck Cancers
9. New Treatments Emerging from Immune and Inflammatory Disease R&D Pipelines
10. Version 2.0 of Award-Winning Proloquo2Go App for iPhone, iPad & iPod touch Speeds Up Communication, Adds New Voices and Customization Options
11. Ear, Nose & Throat Journal publishes research on breakthrough treatment for tonsil stones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... Isodiol International Inc. (CSE: ISOL) ... in the development of pharmaceutical and consumer products, announces the operational numbers of ... 2017. Iso International LLC recorded unaudited fiscal Q1 profits of $897,596 based on ...
(Date:7/26/2017)... ... July 26, 2017 , ... The number of adults 65 years or ... ways to improve asthma control in the population are not well described. In a ... Practice), an official journal of the American Academy of Allergy, Asthma & Immunology (AAAAI), ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... of their partnership to provide the Pharmacist eCare Plan to Computer-Rx ... the country with the ability to develop the Pharmacist eCare Plan, a shared ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... provider in the United States, today announced its partnership with financial technology company, ... , The foundation of the solution lies within Hyosung’s superior ATMs, assisted self-service ...
(Date:7/25/2017)... ... ... SignatureCare Emergency Center – South Austin is treating both adult and pediatric patients ... The Emergency Room opened early March, making it the first SignatureCare Emergency ... are running smoothly,” said Aaron Braun, SignatureCare Emergency Center’s Chief Medical Officer. “We’re glad ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... , July 10, 2017 Locus Biosciences ... Note to support the development of CRISPR-Cas3 antimicrobial therapeutics. ... Limited, a leading Chinese Internet services provider, and joined ... advance multiple infectious disease product programs targeting antibiotic resistant ... Founded by Dr. Rodolphe Barrangou ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of oral drug ... the Israel Securities Authority to dual-list its common stock on ... commence trading on the TASE on July 12, 2017 under ... the Company, it is expected that Oramed will be included ...
(Date:7/1/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... call will be broadcast live over the Internet on Thursday, ... release detailing the quarterly results will be made available at ... The live audio webcast can be accessed via ... will be archived for replay following the conference call. ...
Breaking Medicine Technology: